Featured Research

from universities, journals, and other organizations

Why Gleevec-type Drugs Control, But Do Not Eradicate, Leukemia

Date:
December 11, 2008
Source:
Oregon Health & Science University
Summary:
Researchers are closer to understanding why certain chronic myeloid leukemia mutations are not stopped by the revolutionary targeted cancer pill, Gleevec, or similar therapies in that drug family.

Oregon Health & Science University Knight Cancer Institute researchers are closer to understanding why certain chronic myeloid leukemia mutations are not stopped by the revolutionary targeted cancer pill, Gleevec, or similar therapies in that drug family.

The research was presented Dec. 8, at the 50th Annual American Society of Hematology conference in San Francisco.

Gleevec, also called imatinib, works by shutting down a critical protein, BCR-ABL, which causes leukemia cells to grow uncontrollably. However, Gleevec also affects other proteins, specifically the KIT protein, which exists on the surface of certain cells and binds to a substance that causes them to grow. Researchers wanted to find out if Gleevec's ability to inhibit KIT in addition to BCR-ABL is an important component in its success in stopping this cancer.

"What we found is that only simultaneous inhibition of both proteins effectively suppresses leukemia cell growth, suggesting that the reason imatinib is so clinically successful may be due to its capacity to inhibit both the cancer-causing BCR-ABL and the complementary protein KIT," said Amie Corbin, OHSU Knight Cancer Institute senior research scientist.

"Most of the time we consider 'off-target effects' such as those seen with imatinib against KIT as detrimental because they may cause side effects. Our study indicates that things are a little more complicated: some off-target effects may actually be critical for the efficacy of the drug," said Michael Deininger, M.D., Ph.D., associate professor of medicine (hematology/medical oncology), OHSU School of Medicine; head of the Hematologic Malignancies Section, OHSU Knight Cancer Institute; and Scholar of the Leukemia & Lymphoma Society.

Corbin stresses that this finding should not impact patients currently taking the drugs imatinib or the related drugs dasatini or nilotinib. However, patients should check with their physicians if they have any concerns. All three of the drugs target both BCR-ABL and KIT. However, novel drugs against multidrug resistant mutants of BCR-ABL may not be as effective if they don't also target KIT and this should be considered in pre-clinical drug development.

Researchers also found that while dual BCR-ABL/KIT inhibition was important to suppress the majority of CML cell types that rely on both BCR-ABL and KIT activity, the most primitive CML stem cells that are resistant to imatinib treatment and cause long-term residual disease in imatinib-treated patients were not sensitive to the effects of KIT inhibition.

"This suggests that CML stem cell survival depends on different proteins that are not targets of imatinib and presents a possible explanation for why these cells survive therapy," Corbin said.

Brian Druker, director of the OHSU Knight Cancer Institute, was instrumental in the development of Gleevec (imatinib), and spearheaded the highly successful clinical trials of imatinib for CML.

The research was sponsored by the Leukemia & Lymphoma Society.

Other OHSU Knight Cancer Institute researchers include; Thomas O'Hare., Ph.D., research specialist, Brian Druker, M.D., JELD-WEN Chair of Leukemia Research, Howard Hughes Medical Institute Investigator and a member of the National Academy of Sciences.


Story Source:

The above story is based on materials provided by Oregon Health & Science University. Note: Materials may be edited for content and length.


Cite This Page:

Oregon Health & Science University. "Why Gleevec-type Drugs Control, But Do Not Eradicate, Leukemia." ScienceDaily. ScienceDaily, 11 December 2008. <www.sciencedaily.com/releases/2008/12/081208114252.htm>.
Oregon Health & Science University. (2008, December 11). Why Gleevec-type Drugs Control, But Do Not Eradicate, Leukemia. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2008/12/081208114252.htm
Oregon Health & Science University. "Why Gleevec-type Drugs Control, But Do Not Eradicate, Leukemia." ScienceDaily. www.sciencedaily.com/releases/2008/12/081208114252.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
CDC Calls for New Ebola Safety Guidelines

CDC Calls for New Ebola Safety Guidelines

AP (Oct. 20, 2014) Centers for Disease Control and Prevention Director Dr. Tom Frieden laid out new guidelines for health care workers when dealing with the deadly Ebola virus including new precautions when taking off personal protective equipment. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins